The potential role of dopamine D3 receptor neurotransmission in cognition

European Neuropsychopharmacology

Volumn 23, Issue 8, 2013, Pages 799-813

  Nakajima, Shinichiro ^a,b,c   Gerretsen, Philip ^a,b,d   Takeuchi, Hiroyoshi ^a,b,c   Caravaggio, Fernando ^a,d   Chow, Tiffany ^a,b,d,e   Le Foll, Bernard ^a,b,d   Mulsant, Benoit ^a,b   Pollock, Bruce ^a,b   Graff Guerrero, Ariel ^a,b  

^a CENTRE FOR ADDICTION AND MENTAL HEALTH   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c KEIO UNIVERSITY   (Japan)

^d UNIVERSITY OF TORONTO   (Canada)

^e ROTMAN RESEARCH INSTITUTE   (Canada)

Author keywords

Cognition; Dopamine D3 receptor; Dopamine D3 receptor antagonist

Indexed keywords

1 [4 [4 (6 IMIDAZO[2,1 B]THIAZOLYL)PHENOXY]BUTYL] 4 (2 METHOXYPHENYL)PIPERAZINE; 2 DIPROPYLAMINO 5,6 DIMETHOXYINDAN; 2 DIPROPYLAMINO 7 HYDROXYTETRALIN; 3,4,4A,10B TETRAHYDRO 4 PROPYL 2H,5H [1]BENZOPYRANO[4,3 B][1,4]OXAZIN 9 OL; 7 DIPROPYLAMINO 2,3,5,6,7,8 HEXAHYDRONAPHTHO[2,3 B]FURAN; ACETYLCHOLINE; BP 897; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN BINDING PROTEIN; DOPAMINE 3 RECEPTOR; DOPAMINE 3 RECEPTOR BLOCKING AGENT; DOPAMINE 3 RECEPTOR STIMULATING AGENT; G PROTEIN COUPLED RECEPTOR; GSK 598809; METHAMPHETAMINE; N [4 [2 (6 CYANO 1,2,3,4 TETRAHYDRO 2 ISOQUINOLINYL)ETHYL]CYCLOHEXYL] 4 QUINOLINECARBOXAMIDE; N [4 [2 (8 CYANO 1,3A,4,9B TETRAHYDRO 1 BENZOPYRANO[3,4 C]PYRROL 2(3H) YL)ETHYL]PHENYL]ACETAMIDE; NEFADOTRIDE; S 33084; SCOPOLAMINE; TEPROTUMUMAB; UNCLASSIFIED DRUG;

ACETYLCHOLINE RELEASE; ADDICTION; ALZHEIMER DISEASE; ARTICLE; ATTENTION; BRAIN CORTEX; BRAIN REGION; COGNITION; COGNITIVE DEFECT; DOPAMINERGIC NERVE CELL; ELECTRIC POTENTIAL; EMBASE; EXECUTIVE FUNCTION; FRONTAL LOBE; FUNCTIONAL MAGNETIC RESONANCE IMAGING; GENE FREQUENCY; GENETIC ASSOCIATION; GENOTYPE; HIPPOCAMPUS; HUMAN; LEARNING; MEDLINE; MEMORY; MENTAL PERFORMANCE; NEUROIMAGING; NEUROTRANSMISSION; NONHUMAN; NUCLEUS ACCUMBENS; PASSIVE AVOIDANCE; PREFRONTAL CORTEX; PRIORITY JOURNAL; RECEPTOR BLOCKING; RECOGNITION; SCHIZOPHRENIA; SIGNAL TRANSDUCTION; SOCIAL DISCRIMINATION; SPATIAL MEMORY; THALAMUS; WISCONSIN CARD SORTING TEST; WORKING MEMORY;

COGNITION; DOPAMINE D3 RECEPTOR; DOPAMINE D3 RECEPTOR ANTAGONIST;

ANIMALS; COGNITION; COGNITION DISORDERS; DOPAMINE ANTAGONISTS; HUMANS; MENTAL DISORDERS; MOLECULAR TARGETED THERAPY; NERVE TISSUE PROTEINS; NEURONS; PERFORMANCE-ENHANCING SUBSTANCES; PREFRONTAL CORTEX; RECEPTORS, DOPAMINE D3; SYNAPTIC TRANSMISSION;

EID: 84881664162     PISSN: 0924977X     EISSN: 18737862     Source Type: Journal    
DOI: 10.1016/j.euroneuro.2013.05.006     Document Type: Review

References (164)

1. Backman L., Nyberg L., Lindenberger U., Li S.C., Farde L. The correlative triad among aging, dopamine, and cognition: current status and future prospects. Neurosci. Biobehav. Rev. 2006, 30:791-807.
2. Ball D., Hill L., Eley T.C., Chorney M.J., Chorney K., Thompson L.A., Detterman D.K., Benbow C., Lubinski D., Owen M., McGuffin P., Plomin R. Dopamine markers and general cognitive ability. Neuroreport 1998, 9:347-349.
3. Ballard C., Gauthier S., Corbett A., Brayne C., Aarsland D., Jones E. Alzheimer's disease. Lancet 2011, 377:1019-1031.
4. Banasikowski T.J., Bespalov A., Drescher K., Behl B., Unger L., Haupt A., Schoemaker H., Sullivan J.P., Gross G., Beninger R.J. Double dissociation of the effects of haloperidol and the dopamine D3 receptor antagonist ABT-127 on acquisition vs. expression of cocaine-conditioned activity in rats. J. Pharmacol. Exp. Ther. 2010, 335:506-515.
5. Basile M., Lin R., Kabbani N., Karpa K., Kilimann M., Simpson I., Kester M. Paralemmin interacts with D3 dopamine receptors: implications for membrane localization and cAMP signaling. Arch. Biochem. Biophys. 2006, 446:60-68.
6. Baunez C., Robbins T.W. Effects of dopamine depletion of the dorsal striatum and further interaction with subthalamic nucleus lesions in an attentional task in the rat. Neuroscience 1999, 92:1343-1356.
7. Bernaerts P., Tirelli E. Facilitatory effect of the dopamine D4 receptor agonist PD168,077 on memory consolidation of an inhibitory avoidance learned response in C57BL/6J mice. Behav. Brain Res. 2003, 142:41-52.
8. Bezard E., Ferry S., Mach U., Stark H., Leriche L., Boraud T., Gross C., Sokoloff P. Attenuation of levodopa-induced dyskinesia by normalizing dopamine D3 receptor function. Nat. Med. 2003, 9:762-767.
9. Bhathena A., Wang Y., Kraft J., Idler K., Abel S., Holley-Shanks R., Robieson W., Spear B., Redden L., Katz D. Association between dopamine D3 receptor genotype and response to dopamine D3 receptor antagonist in schizophrenic subjects. Clin. Pharmacol. Ther. 2011, 89(Suppl. 1):S76.
10. Black K.J., Hershey T., Koller J.M., Videen T.O., Mintun M.A., Price J.L., Perlmutter J.S. A possible substrate for dopamine-related changes in mood and behavior: prefrontal and limbic effects of a D3-preferring dopamine agonist. Proc. Natl. Acad. Sci. USA 2002, 99:17113-17118.
11. Boggs D.L., Kelly D.L., McMahon R.P., Gold J.M., Gorelick D.A., Linthicum J., Conley R.R., Liu F., Waltz J., Huestis M.A., Buchanan R.W. Rimonabant for neurocognition in schizophrenia: a 16-week double blind randomized placebo controlled trial. Schizophr. Res. 2012, 134:207-210.
12. Boileau I., Payer D., Houle S., Behzadi A., Rusjan P.M., Tong J., Wilkins D., Selby P., George T.P., Zack M., Furukawa Y., McCluskey T., Wilson A.A., Kish S.J. Higher binding of the dopamine D3 receptor-preferring ligand [11C]-(+)-propyl-hexahydro-naphtho-oxazin in methamphetamine polydrug users: a positron emission tomography study. J. Neurosci. 2012, 32:1353-1359.
13. Boileau I., Guttman M., Rusjan P., Adams J.R., Houle S., Tong J., Hornykiewicz O., Furukawa Y., Wilson A.A., Kapur S., Kish S.J. Decreased binding of the D3 dopamine receptor-preferring ligand [11C]-(+)-PHNO in drug-naive Parkinson's disease. Brain 2009, 132:1366-1375.
14. Bombin I., Arango C., Mayoral M., Castro-Fornieles J., Gonzalez-Pinto A., Gonzalez-Gomez C., Moreno D., Parellada M., Baeza I., Graell M., Otero S., Saiz P.A., Patino-Garcia A. DRD3, but not COMT or DRD2, genotype affects executive functions in healthy and first-episode psychosis adolescents. Am. J. Med. Genet. B: Neuropsychiatr. Genet. 2008, 147B:873-879.
15. Boulougouris, V., Castañé, A., Robbins, T.W., 2009. Dopamine D2/D3 receptor agonist quinpirole impairs spatial reversal learning in rats: investigation of D3 receptor involvement in persistent behavior. Psychopharmacology (Berlin). 202, 611-620.
16. Boussaoud D., Kermadi I. The primate striatum: neuronal activity in relation to spatial attention versus motor preparation. Eur. J. Neurosci. 1997, 9:2152-2168.
17. Bouthenet M.L., Souil E., Martres M.P., Sokoloff P., Giros B., Schwartz J.C. Localization of dopamine D3 receptor mRNA in the rat brain using in situ hybridization histochemistry: comparison with dopamine D2 receptor mRNA. Brain Res. 1991, 564:203-219.
18. Braszko J.J. Participation of D 1-4 dopamine receptors in the pro-cognitive effects of angiotensin IV and des-Phe 6 angiotensin IV. Neurosci. Biobehav. Rev. 2010, 34:343-350.
19. Brusa L., Tiraboschi P., Koch G., Peppe A., Pierantozzi M., Ruggieri S., Stanzione P. Pergolide effect on cognitive functions in early-mild Parkinson's disease. J. Neural Transm. 2005, 112:231-237.
20. Brusa L., Bassi A., Stefani A., Pierantozzi M., Peppe A., Caramia M.D., Boffa L., Ruggieri S., Stanzione P. Pramipexole in comparison to l-dopa: a neuropsychological study. J. Neural Transm. 2003, 110:373-380.
21. Bunten S., Happe S. Rotigotine transdermal system: a short review. Neuropsychiatr. Dis. Treat. 2006, 2:421-426.
22. Burdick K.E., Braga R.J., Nnadi C.U., Shaya Y., Stearns W.H., Malhotra A.K. Placebo-controlled adjunctive trial of pramipexole in patients with bipolar disorder: targeting cognitive dysfunction. J. Clin. Psychiatry 2012, 73:103-112.
23. Castorina A., Leggio G.M., Giunta S., Magro G., Scapagnini G., Drago F., D'Agata V. Neurofibromin and amyloid precursor protein expression in dopamine D3 receptor knock-out mice brains. Neurochem. Res. 2011, 36:426-434.
24. Chiaroni P., Azorin J.M., Dassa D., Henry J.M., Giudicelli S., Malthiery Y., Planells R. Possible involvement of the dopamine D3 receptor locus in subtypes of bipolar affective disorder. Psychiatr. Genet. 2000, 10:43-49.
25. Chourbaji S., Brandwein C., Vogt M.A., Dormann C., Mueller R., Drescher K.U., Gross G., Gass P. Dopamine receptor 3 (D3) knockout mice show regular emotional behaviour. Pharmacol. Res. 2008, 58:302-307.
26. Cole D.M., Beckmann C.F., Searle G.E., Plisson C., Tziortzi A.C., Nichols T.E., Gunn R.N., Matthews P.M., Rabiner E.A., Beaver J.D. Orbitofrontal connectivity with resting-state networks is associated with midbrain dopamine D3 receptor availability. Cereb. Cortex 2011, 22:2784-2793.
27. Cools R., D'Esposito M. Inverted-U-shaped dopamine actions on human working memory and cognitive control. Biol. Psychiatry 2012, 69:e113-e125.
28. Cools R., Altamirano L., D'Esposito M. Reversal learning in Parkinson's disease depends on medication status and outcome valence. Neuropsychologia 2006, 44:1663-1673.
29. Cosentino M., Colombo C., Mauri M., Ferrari M., Corbetta S., Marino F., Bono G., Lecchini S. Expression of apoptosis-related proteins and of mRNA for dopaminergic receptors in peripheral blood mononuclear cells from patients with Alzheimer disease. Alzheimer Dis. Assoc. Disord. 2009, 23:88-90.
30. Costa A., Peppe A., Dell'Agnello G., Caltagirone C., Carlesimo G.A. Dopamine and cognitive functioning in de novo subjects with Parkinson's disease: effects of pramipexole and pergolide on working memory. Neuropsychologia 2009, 47:1374-1381.
31. Czermak C., Wallner S.J., Kresse A., Schauer S., Aigner R., Hoefler G., Lehofer M., Liebmann P.M. Baseline plasma epinephrine levels predict Wisconsin Card Sorting Test scores in healthy volunteers. Psychoneuroendocrinology 2009, 34:625-628.
32. de Krom M., Staal W.G., Ophoff R.A., Hendriks J., Buitelaar J., Franke B., de Jonge M.V., Bolton P., Collier D., Curran S., van Engeland H., van Ree J.M. A common variant in DRD3 receptor is associated with autism spectrum disorder. Biol. Psychiatry 2009, 65:625-630.
33. Demirtas-Tatlidede A., Vahabzadeh-Hagh A., Pascual-Leone A. Can noninvasive brain stimulation enhance cognition in neuropsychiatric disorders?. Neuropharmacology 2012, 64:566-578.
34. Diaz J., Pilon C., Le Foll B., Gros C., Triller A., Schwartz J.C., Sokoloff P. Dopamine D3 receptors expressed by all mesencephalic dopamine neurons. J. Neurosci. 2000, 20:8677-8684.
35. Diaz J., Levesque D., Lammers C.H., Griffon N., Martres M.P., Schwartz J.C., Sokoloff P. Phenotypical characterization of neurons expressing the dopamine D3 receptor in the rat brain. Neuroscience 1995, 65:731-745.
36. Donarum E.A., Halperin R.F., Stephan D.A., Narayanan V. Cognitive dysfunction in NF1 knock-out mice may result from altered vesicular trafficking of APP/DRD3 complex. BMC Neurosci. 2006, 7:22.
37. Dubertret C., Gorwood P., Ades J., Feingold J., Schwartz J.C., Sokoloff P. Meta-analysis of DRD3 gene and schizophrenia: ethnic heterogeneity and significant association in Caucasians. Am. J. Med. Genet. 1998, 81:318-322.
38. El-Ghundi M., O'Dowd B.F., George S.R. Insights into the role of dopamine receptor systems in learning and memory. Rev. Neurosci. 2007, 18:37-66.
39. Ersche K.D., Roiser J.P., Lucas M., Domenici E., Robbins T.W., Bullmore E.T. Peripheral biomarkers of cognitive response to dopamine receptor agonist treatment. Psychopharmacology (Berlin) 2011, 214:779-789.
40. Floresco S.B., Magyar O. Mesocortical dopamine modulation of executive functions: beyond working memory. Psychopharmacology (Berlin) 2006, 188:567-585.
41. Fujisawa S., Buzsaki G. A 4Hz oscillation adaptively synchronizes prefrontal, VTA, and hippocampal activities. Neuron 2011, 72:153-165.
42. Gross G., Drescher K. The role of dopamine D(3) receptors in antipsychotic activity and cognitive functions. Handb Exp Pharmacol. 2012, 213:167-210.
43. Glickstein S.B., Desteno D.A., Hof P.R., Schmauss C. Mice lacking dopamine D2 and D3 receptors exhibit differential activation of prefrontal cortical neurons during tasks requiring attention. Cereb. Cortex 2005, 15:1016-1024.
44. Glickstein S.B., Hof P.R., Schmauss C. Mice lacking dopamine D2 and D3 receptors have spatial working memory deficits. J. Neurosci. 2002, 22:5619-5629.
45. Gobert A., Di Cara B., Cistarelli L., Millan M.J. Piribedil enhances frontocortical and hippocampal release of acetylcholine in freely moving rats by blockade of alpha 2A-adrenoceptors: a dialysis comparison to talipexole and quinelorane in the absence of acetylcholinesterase inhibitors. J. Pharmacol. Exp. Ther. 2003, 305:338-346.
46. Gobert A., Lejeune F., Rivet J.M., Cistarelli L., Millan M.J. Dopamine D3 (auto) receptors inhibit dopamine release in the frontal cortex of freely moving rats in vivo. J. Neurochem. 1996, 66:2209-2212.
47. Gobert A., Rivet J.M., Audinot V., Cistarelli L., Spedding M., Vian J., Peglion J.L., Millan M.J. Functional correlates of dopamine D3 receptor activation in the rat in vivo and their modulation by the selective antagonist, (+)-S 14297: II. Both D2 and "silent" D3 autoreceptors control synthesis and release in mesolimbic, mesocortical and nigrostriatal pathways. J. Pharmacol. Exp. Ther. 1995, 275:899-913.
48. Gong P., Zhang F., Lei X., Wu X., Chen D., Zhang W., Zhang K., Zheng A., Gao X. No observable relationship between the 12 genes of nervous system and reasoning skill in a young Chinese Han population. Cell. Mol. Neurobiol. 2011, 31:519-526.
49. Graff-Guerrero A., Mizrahi R., Agid O., Marcon H., Barsoum P., Rusjan P., Wilson A.A., Zipursky R., Kapur S. The dopamine D2 receptors in high-affinity state and D3 receptors in schizophrenia: a clinical [11C]-(+)-PHNO PET study. Neuropsychopharmacology 2009, 34:1078-1086.
50. Green M.F. Stimulating the development of drug treatments to improve cognition in schizophrenia. Annu. Rev. Clin. Psychol. 2007, 3:159-180.
51. Green M.F., Kern R.S., Heaton R.K. Longitudinal studies of cognition and functional outcome in schizophrenia: implications for MATRICS. Schizophr. Res. 2004, 72:41-51.
52. Green M.F., Kern R.S., Braff D.L., Mintz J. Neurocognitive deficits and functional outcome in schizophrenia: are we measuring the "right stuff"?. Schizophr. Bull. 2000, 26:119-136.
53. Gross G., Wicke K., Drescher K.U. Dopamine D(3) receptor antagonism-still a therapeutic option for the treatment of schizophrenia. Naunyn Schmiedeberg's Arch. Pharmacol. 2013, 386:155-166.
54. Gross G., Drescher K. The role of dopamine D(3) receptors in antipsychotic activity and cognitive functions. Handb. Exp. Pharmacol. 2012, 167-210.
55. Gupta S., Bousman C.A., Chana G., Cherner M., Heaton R.K., Deutsch R., Ellis R.J., Grant I., Everall I.P. Dopamine receptor D3 genetic polymorphism (rs6280TC) is associated with rates of cognitive impairment in methamphetamine-dependent men with HIV: preliminary findings. J. Neurovirol. 2011, 17:239-247.
56. Gurevich E.V., Joyce J.N. Distribution of dopamine D3 receptor expressing neurons in the human forebrain: comparison with D2 receptor expressing neurons. Neuropsychopharmacology 1999, 20:60-80.
57. Gurevich E.V., Bordelon Y., Shapiro R.M., Arnold S.E., Gur R.E., Joyce J.N. Mesolimbic dopamine D3 receptors and use of antipsychotics in patients with schizophrenia. A postmortem study. Arch. Gen. Psychiatry 1997, 54:225-232.
58. Gyertyan I., Saghy K., Laszy J., Elekes O., Kedves R., Gemesi L.I., Pasztor G., Zajer-Balazs M., Kapas M., Agai Csongor E., Domany G., Kiss B., Szombathelyi Z. Subnanomolar dopamine D3 receptor antagonism coupled to moderate D2 affinity results in favourable antipsychotic-like activity in rodent models: II. Behavioural characterisation of RG-15. Naunyn Schmiedeberg's Arch. Pharmacol. 2008, 378:529-539.
59. Gyertyan I., Saghy K. The selective dopamine D3 receptor antagonists, SB 277011-A and S 33084 block haloperidol-induced catalepsy in rats. Eur. J. Pharmacol. 2007, 572:171-174.
60. Hall H., Halldin C., Dijkstra D., Wikstrom H., Wise L.D., Pugsley T.A., Sokoloff P., Pauli S., Farde L., Sedvall G. Autoradiographic localisation of D3-dopamine receptors in the human brain using the selective D3-dopamine receptor agonist (+)-[3H]PD 128907. Psychopharmacology (Berlin) 1996, 128:240-247.
61. Hale, M.W, Crowe, S,F., 2002. The effects of selective dopamine agonists on a passive avoidance learning task in the day-old chick. Behav. Pharmacol. 13, 295-301.
62. Hamidovic A., Kang U.J., de Wit H. Effects of low to moderate acute doses of pramipexole on impulsivity and cognition in healthy volunteers. J. Clin. Psychopharmacol. 2008, 28:45-51.
63. Heidbreder C. Rationale in support of the use of selective dopamine D(3) receptor antagonists for the pharmacotherapeutic management of substance use disorders. Naunyn Schmiedeberg's Arch. Pharmacol. 2013, 386:167-176.
64. Heidbreder C.A., Newman A.H. Current perspectives on selective dopamine D(3) receptor antagonists as pharmacotherapeutics for addictions and related disorders. Ann. N. Y. Acad. Sci. 2010, 1187:4-34.
65. Heidbreder C.A., Gardner E.L., Xi Z.X., Thanos P.K., Mugnaini M., Hagan J.J., Ashby C.R. The role of central dopamine D3 receptors in drug addiction: a review of pharmacological evidence. Brain Res. Brain Res. Rev. 2005, 49:77-105.
66. Hubble J.P. Pre-clinical studies of pramipexole: clinical relevance. Eur. J. Neurol. 2000, 7(Suppl. 1):15-20.
67. Ilani T., Ben-Shachar D., Strous R.D., Mazor M., Sheinkman A., Kotler M., Fuchs S. A peripheral marker for schizophrenia: increased levels of D3 dopamine receptor mRNA in blood lymphocytes. Proc. Natl. Acad. Sci. USA 2001, 98:625-628.
68. Jeanneteau F., Funalot B., Jankovic J., Deng H., Lagarde J.P., Lucotte G., Sokoloff P. A functional variant of the dopamine D3 receptor is associated with risk and age-at-onset of essential tremor. Proc. Natl. Acad. Sci. USA 2006, 103:10753-10758.
69. Joseph J.D., Wang Y.M., Miles P.R., Budygin E.A., Picetti R., Gainetdinov R.R., Caron M.G., Wightman R.M. Dopamine autoreceptor regulation of release and uptake in mouse brain slices in the absence of D(3) receptors. Neuroscience 2002, 112:39-49.
70. Joyce J.N., Millan M.J. Dopamine D3 receptor antagonists as therapeutic agents. Drug Discov. Today 2005, 10:917-925.
71. Joyce J.N. Dopamine D3 receptor as a therapeutic target for antipsychotic and antiparkinsonian drugs. Pharmacol. Ther. 2001, 90:231-259.
72. Kaduszkiewicz H., Zimmermann T., Beck-Bornholdt H.P., Van Den Bussche H. Cholinesterase inhibitors for patients with Alzheimer's disease: systematic review of randomised clinical trials. Br. Med. J. 2005, 331:321-327.
73. Keefe R.S., Harvey P.D. Cognitive impairment in schizophrenia. Handb. Exp. Pharmacol. 2012, 213:11-37.
74. Keri S., Juhasz A., Rimanoczy A., Szekeres G., Kelemen O., Cimmer C., Szendi I., Benedek G., Janka Z. Habit learning and the genetics of the dopamine D3 receptor: evidence from patients with schizophrenia and healthy controls. Behav. Neurosci. 2005, 119:687-693.
75. Khaled M.A., Farid Araki K., Li B., Coen K.M., Marinelli P.W., Varga J., Gaal J., Le Foll B. The selective dopamine D3 receptor antagonist SB 277011-A, but not the partial agonist BP 897, blocks cue-induced reinstatement of nicotine-seeking. Int. J. Neuropsychopharmacol. 2010, 13:181-190.
76. Khan Z.U., Gutierrez A., Martin R., Penafiel A., Rivera A., De La Calle A. Differential regional and cellular distribution of dopamine D2-like receptors: an immunocytochemical study of subtype-specific antibodies in rat and human brain. J. Comp. Neurol. 1998, 402:353-371.
77. Kim B., Choi E.Y., Kim C.Y., Song K., Joo Y.H. Could HTR2A T102C and DRD3 Ser9Gly predict clinical improvement in patients with acutely exacerbated schizophrenia? Results from treatment responses to risperidone in a naturalistic setting. Hum. Psychopharmacol. 2008, 23:61-67.
78. Koeltzow T.E., Xu M., Cooper D.C., Hu X.T., Tonegawa S., Wolf M.E., White F.J. Alterations in dopamine release but not dopamine autoreceptor function in dopamine D3 receptor mutant mice. J. Neurosci. 1998, 18:2231-2238.
79. Kumar U., Patel S.C. Immunohistochemical localization of dopamine receptor subtypes (D1R-D5R) in Alzheimer's disease brain. Brain Res. 2007, 1131:187-196.
80. Lacroix L.P., Ceolin L., Zocchi A., Varnier G., Garzotti M., Curcuruto O., Heidbreder C.A. Selective dopamine D3 receptor antagonists enhance cortical acetylcholine levels measured with high-performance liquid chromatography/tandem mass spectrometry without anti-cholinesterases. J. Neurosci. Methods 2006, 157:25-31.
81. Lacroix L.P., Hows M.E., Shah A.J., Hagan J.J., Heidbreder C.A. Selective antagonism at dopamine D3 receptors enhances monoaminergic and cholinergic neurotransmission in the rat anterior cingulate cortex. Neuropsychopharmacology 2003, 28:839-849.
82. Lane H.Y., Liu Y.C., Huang C.L., Hsieh C.L., Chang Y.L., Chang L., Chang Y.C., Chang W.H. Prefrontal executive function and D1, D3, 5-HT2A and 5-HT6 receptor gene variations in healthy adults. J. Psychiatry Neurosci. 2008, 33:47-53.
83. Laszy J., Laszlovszky I., Gyertyan I. Dopamine D3 receptor antagonists improve the learning performance in memory-impaired rats. Psychopharmacology (Berlin) 2005, 179:567-575.
84. Le Foll B., Gallo A., Le Strat Y., Lu L., Gorwood P. Genetics of dopamine receptors and drug addiction: a comprehensive review. Behav. Pharmacol. 2009, 20:1-17.
85. Le Foll B., Diaz J., Sokoloff P. Neuroadaptations to hyperdopaminergia in dopamine D3 receptor-deficient mice. Life Sci. 2005, 76:1281-1296.
86. Le Foll B., Goldberg S.R., Sokoloff P. The dopamine D3 receptor and drug dependence: effects on reward or beyond?. Neuropharmacology 2005, 49:525-541.
87. Le Foll B., Schwartz J.C., Sokoloff P. Disruption of nicotine conditioning by dopamine D(3) receptor ligands. Mol. Psychiatry 2003, 8:225-230.
88. Le Foll B., Frances H., Diaz J., Schwartz J.C., Sokoloff P. Role of the dopamine D3 receptor in reactivity to cocaine-associated cues in mice. Eur. J. Neurosci. 2002, 15:2016-2026.
89. Lee B., Butcher G.Q., Hoyt K.R., Impey S., Obrietan K. Activity-dependent neuroprotection and cAMP response element-binding protein (CREB): kinase coupling, stimulus intensity, and temporal regulation of CREB phosphorylation at serine 133. J. Neurosci. 2005, 25:1137-1148.
90. Levant B. Differential distribution of D3 dopamine receptors in the brains of several mammalian species. Brain Res. 1998, 800:269-274.
91. Levesque D., Diaz J., Pilon C., Martres M.P., Giros B., Souil E., Schott D., Morgat J.L., Schwartz J.C., Sokoloff P. Identification, characterization, and localization of the dopamine D3 receptor in rat brain using 7-[3H]hydroxy-N,N-di-n-propyl-2-aminotetralin. Proc. Natl. Acad. Sci. USA 1992, 89:8155-8159.
92. Lieberman J.A., Dunbar G., Segreti A.C., Girgis R.R., Seoane F., Beaver J.S., Duan N., Hosford D.A. A randomized exploratory trial of an alpha-7 nicotinic receptor agonist (TC-5619) for cognitive enhancement in schizophrenia. Neuropsychopharmacology 2013, 38:968-975.
93. Limosin F., Romo L., Batel P., Ades J., Boni C., Gorwood P. Association between dopamine receptor D3 gene BalI polymorphism and cognitive impulsiveness in alcohol-dependent men. Eur. Psychiatry 2005, 20:304-306.
94. Loiseau F., Millan M.J. Blockade of dopamine D(3) receptors in frontal cortex, but not in sub-cortical structures, enhances social recognition in rats: similar actions of D(1) receptor agonists, but not of D(2) antagonists. Eur. Neuropsychopharmacol. 2009, 19:23-33.
95. Lundstrom K., Turpin M.P., Large C., Robertson G., Thomas P., Lewell X.Q. Mapping of dopamine D3 receptor binding site by pharmacological characterization of mutants expressed in CHO cells with the Semliki Forest virus system. J. Recept. Signal Transduct. Res. 1998, 18:133-150.
96. Lundstrom K., Turpin M.P. Proposed schizophrenia-related gene polymorphism: expression of the Ser9Gly mutant human dopamine D3 receptor with the Semliki Forest virus system. Biochem. Biophys. Res. Commun. 1996, 225:1068-1072.
97. Marcellino D., Ferre S., Casado V., Cortes A., Le Foll B., Mazzola C., Drago F., Saur O., Stark H., Soriano A., Barnes C., Goldberg S.R., Lluis C., Fuxe K., Franco R. Identification of dopamine D1-D3 receptor heteromers. Indications for a role of synergistic D1-D3 receptor interactions in the striatum. J. Biol. Chem. 2008, 283:26016-26025.
98. Marcondes M.C., Flynn C., Watry D.D., Zandonatti M., Fox H.S. Methamphetamine increases brain viral load and activates natural killer cells in simian immunodeficiency virus-infected monkeys. Am. J. Pathol. 2010, 177:355-361.
99. McShane R., Areosa Sastre A., Minakaran N. Memantine for dementia. Cochrane Database Syst Rev. 2006, 19.
100. Micale V., Cristino L., Tamburella A., Petrosino S., Leggio G.M., Di Marzo V., Drago F. Enhanced cognitive performance of dopamine D3 receptor "knock-out" mice in the step-through passive-avoidance test: assessing the role of the endocannabinoid/endovanilloid systems. Pharmacol. Res. 2010, 61:531-536.
101. Millan M.J., Agid Y., Brune M., Bullmore E.T., Carter C.S., Clayton N.S., Connor R., Davis S., Deakin B., DeRubeis R.J., Dubois B., Geyer M.A., Goodwin G.M., Gorwood P., Jay T.M., Joels M., Mansuy I.M., Meyer-Lindenberg A., Murphy D., Rolls E., Saletu B., Spedding M., Sweeney J., Whittington M., Young L.J. Cognitive dysfunction in psychiatric disorders: characteristics, causes and the quest for improved therapy. Nat. Rev. Drug Discov. 2012, 11:141-168.
102. Millan M.J., Buccafusco J.J., Loiseau F., Watson D.J., Decamp E., Fone K.C., Thomasson-Perret N., Hill M., Mocaer E., Schneider J.S. The dopamine D3 receptor antagonist, S33138, counters cognitive impairment in a range of rodent and primate procedures. Int. J. Neuropsychopharmacol. 2010, 13:1035-1051.
103. Millan M.J., Brocco M. Cognitive impairment in schizophrenia: a review of developmental and genetic models, and pro-cognitive profile of the optimised D(3)>D(2) antagonist, S33138. Therapie 2008, 63:187-229.
104. Millan M.J., Svenningsson P., Ashby C.R., Hill M., Egeland M., Dekeyne A., Brocco M., Di Cara B., Lejeune F., Thomasson N., Munoz C., Mocaer E., Crossman A., Cistarelli L., Girardon S., Iob L., Veiga S., Gobert A. S33138 [N-[4-[2-[(3aS,9bR)-8-cyano-1,3a,4,9b-tetrahydro[1]-benzopyrano[3,4-c]pyrrol-2(3H)-yl)-ethyl]phenylacetamide], a preferential dopamine D3 versus D2 receptor antagonist and potential antipsychotic agent. II. A neurochemical, electrophysiological and behavioral characterization in vivo. J. Pharmacol. Exp. Ther. 2008, 324:600-611.
105. Millan M.J., Di Cara B., Dekeyne A., Panayi F., De Groote L., Sicard D., Cistarelli L., Billiras R., Gobert A. Selective blockade of dopamine D(3) versus D(2) receptors enhances frontocortical cholinergic transmission and social memory in rats: a parallel neurochemical and behavioural analysis. J. Neurochem. 2007, 100:1047-1061.
106. Millan M.J., Dekeyne A., Rivet J.M., Dubuffet T., Lavielle G., Brocco M. S33084, a novel, potent, selective, and competitive antagonist at dopamine D(3)-receptors: II. Functional and behavioral profile compared with GR218,231 and L741,626. J. Pharmacol. Exp. Ther. 2000, 293:1063-1073.
107. Millan M.J., Peglion J.L., Vian J., Rivet J.M., Brocco M., Gobert A., Newman-Tancredi A., Dacquet C., Bervoets K., Girardon S. Functional correlates of dopamine D3 receptor activation in the rat in vivo and their modulation by the selective antagonist, (+)-S 14297: 1. Activation of postsynaptic D3 receptors mediates hypothermia, whereas blockade of D2 receptors elicits prolactin secretion and catalepsy. J. Pharmacol. Exp. Ther. 1995, 275:885-898.
108. Mizrahi R., Agid O., Borlido C., Suridjan I., Rusjan P., Houle S., Remington G., Wilson A.A., Kapur S. Effects of antipsychotics on D3 receptors: a clinical PET study in first episode antipsychotic naive patients with schizophrenia using [11C]-(+)-PHNO. Schizophr. Res. 2011, 131:63-68.
109. Morissette M., Goulet M., Grondin R., Blanchet P., Bedard P.J., Di Paolo T., Levesque D. Associative and limbic regions of monkey striatum express high levels of dopamine D3 receptors: effects of MPTP and dopamine agonist replacement therapies. Eur. J. Neurosci. 1998, 10:2565-2573.
110. Morozova M.A., Beniashvili A.G., Lepilkina T.A., Rupchev G.E. Double-blind placebo-controlled randomized efficacy and safety trial of add-on treatment of dimebon plus risperidone in schizophrenic patients during transition from acute psychotic episode to remission. Psychiatr. Danub. 2012, 24:159-166.
111. Mugnaini M., Iavarone L., Cavallini P., Griffante C., Oliosi B., Savoia C., Beaver J., Rabiner E.A., Micheli F., Heidbreder C., Andorn A., Merlo Pich E., Bani M. Occupancy of brain dopamine D3 receptors and drug craving: a translational approach. Neuropsychopharmacology 2013, 38:302-312.
112. Murray A.M., Ryoo H.L., Gurevich E., Joyce J.N. Localization of dopamine D3 receptors to mesolimbic and D2 receptors to mesostriatal regions of human forebrain. Proc. Natl. Acad. Sci. USA 1994, 91:11271-11275.
113. Murray A.M., Ryoo H., Joyce J.N. Visualization of dopamine D3-like receptors in human brain with [125I]epidepride. Eur. J. Pharmacol. 1992, 227:443-445.
114. Nissbrandt H., Ekman A., Eriksson E., Heilig M. Dopamine D3 receptor antisense influences dopamine synthesis in rat brain. Neuroreport 1995, 6:573-576.
115. Perio A., Terranova J.P., Worms P., Bluthe R.M., Dantzer R., Biziere K. Specific modulation of social memory in rats by cholinomimetic and nootropic drugs, by benzodiazepine inverse agonists, but not by psychostimulants. Psychopharmacology (Berlin) 1989, 97:262-268.
116. Pieramico V., Esposito R., Sensi F., Cilli F., Mantini D., Mattei P.A., Frazzini V., Ciavardelli D., Gatta V., Ferretti A., Romani G.L., Sensi S.L. Combination training in aging individuals modifies functional connectivity and cognition, and is potentially affected by dopamine-related genes. PLoS One 2012, 7:e43901.
117. Piggott M.A., Marshall E.F., Thomas N., Lloyd S., Court J.A., Jaros E., Burn D., Johnson M., Perry R.H., McKeith I.G., Ballard C., Perry E.K. Striatal dopaminergic markers in dementia with Lewy bodies, Alzheimer's and Parkinson's diseases: rostrocaudal distribution. Brain 1999, 122(Pt. 8):1449-1468.
118. Prickaerts J., van Goethem N.P., Chesworth R., Shapiro G., Boess F.G., Methfessel C., Reneerkens O.A., Flood D.G., Hilt D., Gawryl M., Bertrand S., Bertrand D., Konig G. EVP-6124, a novel and selective alpha7 nicotinic acetylcholine receptor partial agonist, improves memory performance by potentiating the acetylcholine response of alpha7 nicotinic acetylcholine receptors. Neuropharmacology 2012, 62:1099-1110.
119. Pugsley T.A., Davis M.D., Akunne H.C., MacKenzie R.G., Shih Y.H., Damsma G., Wikstrom H., Whetzel S.Z., Georgic L.M., Cooke L.W., et al. Neurochemical and functional characterization of the preferentially selective dopamine D3 agonist PD 128907. J. Pharmacol. Exp. Ther. 1995, 275:1355-1366.
120. Rabiner E.A., Slifstein M., Nobrega J., Plisson C., Huiban M., Raymond R., Diwan M., Wilson A.A., McCormick P., Gentile G., Gunn R.N., Laruelle M.A. In vivo quantification of regional dopamine-D3 receptor binding potential of (+)-PHNO: studies in non-human primates and transgenic mice. Synapse 2009, 63:782-793.
121. Reavill C., Taylor S.G., Wood M.D., Ashmeade T., Austin N.E., Avenell K.Y., Boyfield I., Branch C.L., Cilia J., Coldwell M.C., Hadley M.S., Hunter A.J., Jeffrey P., Jewitt F., Johnson C.N., Jones D.N., Medhurst A.D., Middlemiss D.N., Nash D.J., Riley G.J., Routledge C., Stemp G., Thewlis K.M., Trail B., Vong A.K., Hagan J.J. Pharmacological actions of a novel, high-affinity, and selective human dopamine D(3) receptor antagonist, SB-277011-A. J. Pharmacol. Exp. Ther. 2000, 294:1154-1165.
122. Rektorova I., Rektor I., Bares M., Dostal V., Ehler E., Fanfrdlova Z., Fiedler J., Klajblova H., Kulist'ak P., Ressner P., Svatova J., Urbanek K., Veliskova J. Cognitive performance in people with Parkinson's disease and mild or moderate depression: effects of dopamine agonists in an add-on to l-dopa therapy. Eur. J. Neurol. 2005, 12:9-15.
123. Richtand N.M., Woods S.C., Berger S.P., Strakowski S.M. D3 dopamine receptor, behavioral sensitization, and psychosis. Neurosci. Biobehav. Rev. 2001, 25:427-443.
124. Richtand N.M., Kelsoe J.R., Segal D.S., Kuczenski R. Regional quantification of D1, D2, and D3 dopamine receptor mRNA in rat brain using a ribonuclease protection assay. Brain Res. Mol. Brain Res. 1995, 33:97-103.
125. Rybakowski J.K., Borkowska A., Czerski P.M., Kapelski P., Dmitrzak-Weglarz M., Hauser J. An association study of dopamine receptors polymorphisms and the Wisconsin Card Sorting Test in schizophrenia. J. Neural Transm. 2005, 112:1575-1582.
126. Saddichha S., Pandey V. Alzheimer's and non-alzheimer's dementia: a critical review of pharmacological and nonpharmacological strategies. Am. J. Alzheimers Dis. Other Demen. 2008, 23:150-161.
127. Samuels E.R., Hou R.H., Langley R.W., Szabadi E., Bradshaw C.M. Comparison of pramipexole with and without domperidone co-administration on alertness, autonomic, and endocrine functions in healthy volunteers. Br. J. Clin. Pharmacol. 2007, 64:591-602.
128. Samuels E.R., Hou R.H., Langley R.W., Szabadi E., Bradshaw C.M. Comparison of pramipexole and amisulpride on alertness, autonomic and endocrine functions in healthy volunteers. Psychopharmacology (Berlin) 2006, 187:498-510.
129. Samuels E.R., Hou R.H., Langley R.W., Szabadi E., Bradshaw C.M. Comparison of pramipexole and modafinil on arousal, autonomic, and endocrine functions in healthy volunteers. J. Psychopharmacol. 2006, 20:756-770.
130. Sanford M., Scott L.J. Rotigotine transdermal patch: a review of its use in the treatment of Parkinson's disease. CNS Drugs 2011, 25:699-719.
131. Scheller D., Ullmer C., Berkels R., Gwarek M., Lubbert H. The in vitro receptor profile of rotigotine: a new agent for the treatment of Parkinson's disease. Naunyn Schmiedeberg's Arch. Pharmacol. 2009, 379:73-86.
132. Schotte A., Janssen P.F., Bonaventure P., Leysen J.E. Endogenous dopamine limits the binding of antipsychotic drugs to D3 receptors in the rat brain: a quantitative autoradiographic study. Histochem. J. 1996, 28:791-799.
133. Seeley W.W., Menon V., Schatzberg A.F., Keller J., Glover G.H., Kenna H., Reiss A.L., Greicius M.D. Dissociable intrinsic connectivity networks for salience processing and executive control. J. Neurosci. 2007, 27:2349-2356.
134. Serretti A., Macciardi F., Cusin C., Lattuada E., Souery D., Lipp O., Mahieu B., Van Broeckhoven C., Blackwood D., Muir W., Aschauer H.N., Heiden A.M., Ackenheil M., Fuchshuber S., Raeymaekers P., Verheyen G., Kaneva R., Jablensky A., Papadimitriou G.N., Dikeos D.G., Stefanis C.N., Smeraldi E., Mendlewicz J. Linkage of mood disorders with D2, D3 and TH genes: a multicenter study. J. Affect. Disord. 2000, 58:51-61.
135. Sesack S.R., Grace A.A. Cortico-basal ganglia reward network: microcircuitry. Neuropsychopharmacology 2010, 35:27-47.
136. Sigala S., Missale C., Spano P. Opposite effects of dopamine D2 and D3 receptors on learning and memory in the rat. Eur. J. Pharmacol. 1997, 336:107-112.
137. Smith A.G., Neill J.C., Costall B. The dopamine D3/D2 receptor agonist 7-OH-DPAT induces cognitive impairment in the marmoset. Pharmacol Biochem Behav. 1999, 63:201-211.
138. Soffie M., Bronchart M. Age-related scopolamine effects on social and individual behaviour in rats. Psychopharmacology (Berlin) 1988, 95:344-350.
139. Sokoloff P., Leriche L., Diaz J., Louvel J., Pumain R. Direct and indirect interactions of the dopamine D(3) receptor with glutamate pathways: implications for the treatment of schizophrenia. Naunyn Schmiedeberg's Arch. Pharmacol. 2013, 386:107-124.
140. Sokoloff P., Diaz J., Le Foll B., Guillin O., Leriche L., Bezard E., Gross C. The dopamine D3 receptor: a therapeutic target for the treatment of neuropsychiatric disorders. CNS Neurol. Disord. Drug Targets 2006, 5:25-43.
141. Sokoloff P., Giros B., Martres M.P., Bouthenet M.L., Schwartz J.C. Molecular cloning and characterization of a novel dopamine receptor (D3) as a target for neuroleptics. Nature 1990, 347:146-151.
142. Stanwood G.D., Artymyshyn R.P., Kung M.P., Kung H.F., Lucki I., McGonigle P. Quantitative autoradiographic mapping of rat brain dopamine D3 binding with [(125)I]7-OH-PIPAT: evidence for the presence of D3 receptors on dopaminergic and nondopaminergic cell bodies and terminals. J. Pharmacol. Exp. Ther. 2000, 295:1223-1231.
143. Stragier B., Demaegdt H., De Bundel D., Smolders I., Sarre S., Vauquelin G., Ebinger G., Michotte Y., Vanderheyden P. Involvement of insulin-regulated aminopeptidase and/or aminopeptidase N in the angiotensin IV-induced effect on dopamine release in the striatum of the rat. Brain Res. 2007, 1131:97-105.
144. Suzuki M., Hurd Y.L., Sokoloff P., Schwartz J.C., Sedvall G. D3 dopamine receptor mRNA is widely expressed in the human brain. Brain Res. 1998, 779:58-74.
145. Svenningsson P., Westman E., Ballard C., Aarsland D. Cognitive impairment in patients with Parkinson's disease: diagnosis, biomarkers, and treatment. Lancet Neurol. 2012, 11:697-707.
146. Swant J., Stramiello M., Wagner J.J. Postsynaptic dopamine D3 receptor modulation of evoked IPSCs via GABA(A) receptor endocytosis in rat hippocampus. Hippocampus 2008, 18:492-502.
147. Szekeres G., Keri S., Juhasz A., Rimanoczy A., Szendi I., Czimmer C., Janka Z. Role of dopamine D3 receptor (DRD3) and dopamine transporter (DAT) polymorphism in cognitive dysfunctions and therapeutic response to atypical antipsychotics in patients with schizophrenia. Am. J. Med. Genet. B: Neuropsychiatr. Genet. 2004, 124B:1-5.
148. Takahashi H., Yamada M., Suhara T. Functional significance of central D1 receptors in cognition: beyond working memory. J. Cereb. Blood Flow Metab. 2012, 32:1248-1258.
149. Taubenfeld S.M., Wiig K.A., Bear M.F., Alberini C.M. A molecular correlate of memory and amnesia in the hippocampus. Nat. Neurosci. 1999, 2:309-310.
150. Tregellas J.R., Tanabe J., Rojas D.C., Shatti S., Olincy A., Johnson L., Martin L.F., Soti F., Kem W.R., Leonard S., Freedman R. Effects of an alpha 7-nicotinic agonist on default network activity in schizophrenia. Biol. Psychiatry 2011, 69:7-11.
151. Trenkwalder C., Kies B., Rudzinska M., Fine J., Nikl J., Honczarenko K., Dioszeghy P., Hill D., Anderson T., Myllyla V., Kassubek J., Steiger M., Zucconi M., Tolosa E., Poewe W., Surmann E., Whitesides J., Boroojerdi B., Chaudhuri K.R. Rotigotine effects on early morning motor function and sleep in Parkinson's disease: a double-blind, randomized, placebo-controlled study (RECOVER). Mov. Disord. 2011, 26:90-99.
152. Ukai M., Tanaka T., Kameyama T. Effects of the dopamine D3 receptor agonist, R(+)-7-hydroxy-N,N-di-n-propyl-2-aminotetralin, on memory processes in mice. Eur. J. Pharmacol. 1997, 324:147-151.
153. Vanhauwe J.F., Josson K., Luyten W.H., Driessen A.J., Leysen J.E. G-protein sensitivity of ligand binding to human dopamine D(2) and D(3) receptors expressed in Escherichia coli: clues for a constrained D(3) receptor structure. J. Pharmacol. Exp. Ther. 2000, 295:274-283.
154. Velligan D., Brenner R., Sicuro F., Walling D., Riesenberg R., Sfera A., Merideth C., Sweitzer D., Jaeger J. Assessment of the effects of AZD3480 on cognitive function in patients with schizophrenia. Schizophr. Res. 2012, 134:59-64.
155. Walton M., Woodgate A.M., Muravlev A., Xu R., During M.J., Dragunow M. CREB phosphorylation promotes nerve cell survival. J. Neurochem. 1999, 73:1836-1842.
156. Watson D.J., Loiseau F., Ingallinesi M., Millan M.J., Marsden C.A., Fone K.C. Selective blockade of dopamine D3 receptors enhances while D2 receptor antagonism impairs social novelty discrimination and novel object recognition in rats: a key role for the prefrontal cortex. Neuropsychopharmacology 2012, 37:770-786.
157. Watson D.J., Marsden C.A., Millan M.J., Fone K.C. Blockade of dopamine D but not D receptors reverses the novel object discrimination impairment produced by post-weaning social isolation: implications for schizophrenia and its treatment. Int. J. Neuropsychopharmacol. 2012, 15:471-484.
158. Wilson A.A., McCormick P., Kapur S., Willeit M., Garcia A., Hussey D., Houle S., Seeman P., Ginovart N. Radiosynthesis and evaluation of [11C]-(+)-4-propyl-3,4,4a,5,6,10b-hexahydro-2H-naphtho[1,2-b][1,4]oxazin-9-ol as a potential radiotracer for in vivo imaging of the dopamine D2 high-affinity state with positron emission tomography. J. Med. Chem. 2005, 48:4153-4160.
159. Winslow J.T., Camacho F. Cholinergic modulation of a decrement in social investigation following repeated contacts between mice. Psychopharmacology (Berlin) 1995, 121:164-172.
160. Xing B., Kong H., Meng X., Wei S.G., Xu M., Li S.B. Dopamine D1 but not D3 receptor is critical for spatial learning and related signaling in the hippocampus. Neuroscience 2010, 169:1511-1519.
161. Xing B., Meng X., Wei S., Li S. Influence of dopamine D3 receptor knockout on age-related decline of spatial memory. Neurosci. Lett. 2010, 481:149-153.
162. Yi Z., Fan X., Wang J., Liu D., Freudenreich O., Goff D., Henderson D.C. Rosiglitazone and cognitive function in clozapine-treated patients with schizophrenia: a pilot study. Psychiatry Res. 2012, 79-82.
163. Zagmutt F.J., Tarrants M.L. Indirect comparisons of adverse events and dropout rates in early Parkinson's disease trials of pramipexole, ropinirole, and rasagiline. Int. J. Neurosci. 2012, 122:345-353.
164. Zhu X., Li T., Peng S., Ma X., Chen X., Zhang X. Maternal deprivation-caused behavioral abnormalities in adult rats relate to a non-methylation-regulated D2 receptor levels in the nucleus accumbens. Behav. Brain Res. 2010, 209:281-288.